Outlook Therapeutics, Inc. (OTLK), Friday said it has resubmitted its Biologics License Application (BLA) to the U.S.Food and Drug Administration or FDA for ONS-5010 to treat wet age-related macular degeneration (wet AMD).
A decision from the regulator is expected within six months.
The ONS-5010 BLA resubmission is based on the efficacy and safety demonstrated in NORSE EIGHT study, as well as additional chemistry, manufacturing and controls (CMC) information requested by the FDA. The FDA had previously issued a Complete Response Letter (CRL) citing several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.